SECURITIES AND EXCHANGE COMMISSION Washington, D.C.  20549  FORM 10-QSB  (Mark One)  X       QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934  For quarterly period ended November 30, 2006  ____       TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934  For the transition period from _____ to _____  OCTILLION CORP. AND SUBSIDIARIES (Exact name of registrant as specified in its charter)  Nevada (State or other jurisdiction of incorporation)  333-127953 (Commission File Number)  59-3509694 (I.R.S Employer Identification No.)  1628 West 1st Avenue, Suite 216, Vancouver, British Columbia, V6J 1G1 (Address of principal executive offices)  (800) 213-0689 (Registrants telephone number, including area code)   Indicate by check mark whether the registrant: (1) has filed all reports required by Section 13 or 15 (d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes  [X]    No  Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act) Yes  [  ]    No [X]  State the number of shares outstanding of each of the Issuers classes of common equity as of the latest practicable date. As of January 11, 2007, there were 49,374,600 shares of the Issuers Common Stock, $0.001 par value per share outstanding.  Transitional Small Business Disclosure Format (Check One): Yes [  ]    No [X]     TABLE OF CONTENTS  OCTILLION CORP. AND SUBSIDIARIES  FORM 10-QSB, QUARTER ENDED NOVEMBER 30, 2006   PART I    FINANCIAL INFORMATION  Item 1. Financial Statements  Interim Unaudited Consolidated Balance Sheet 3  Interim Unaudited Consolidated Statements of Operations 4   For the Three Months Ended November 30, 2006 and 2005, and For the Period from Inception (May 5, 1998) to November 30, 2006  Interim Unaudited Consolidated Statement of Stockholders Equity (Deficiency) 5 from Inception (May 5, 1998) to November 30, 2006  Interim Unaudited Consolidated Statements of Cash Flows 7 For the Three Months Ended November 30, 2006 and 2005, and For the Period from Inception (May 5, 1998) to November 30, 2006  Notes to Interim Unaudited Consolidated Financial Statements 8  Item 2.  Management's Discussion and Analysis or Plan of Operation 12  Item 3.  Controls and Procedures 22   PART II   OTHER INFORMATION  Item 1. Legal Proceedings 23  Item 2. Unregistered Sales of Equity Securities and Use of Proceeds 23  Item 3. Defaults Upon Senior Securities 23  Item 4. Submission of Matters to a Vote of Security Holders 23  Item 5. Other Information 23  Item 6. Exhibits and Reports on Form 8-K 23  Signatures 24


Item 1. Financial Statements  In the opinion of management, the accompanying unaudited consolidated interim financial statements included in this Form 10-QSB reflect all adjustments (consisting only of normal recurring accruals) necessary for a fair presentation of the results of operations for the periods are presented.  The results of operations for the periods presented are not necessarily indicative of the results to be expected for the full year.  OCTILLION CORP.(A Development Stage Company)CONSOLIDATED BALANCE SHEETNovember 30, 2006(Expressed in U.S. Dollars)(See Note 1 - Nature of Business and Basis of Presentation)(Unaudited)November 30, 2006ASSETSCurrent AssetsCash$337,302Prepaid expenses-337,302Equipment (Note 5)876Total Assets$338,178LIABILITIES AND STOCKHOLDERS' EQUITYCurrent LiabilitiesAccounts payable and accrued liabilities$173,395Accounts payable - related party (Note 8)30,000Total Liabilities203,395Stockholders' EquityAuthorized:100,000,000 preferred shares, with par value of $0.10 per share1,000,000 common shares, with par value of $0.001 per shareIssued: 47,694,600 common shares47,695Additional paid-in capital1,313,137Subscription receivable(229,500)Deficit accumulated during the development stage(996,549)Total Stockholders' Equity134,783Total Liabilities and Stockholders' Equity$338,178(The accompanying notes are an integral part of these consolidated financial statements)  3    OCTILLION CORP.(A Development Stage Company)CONSOLIDATED STATEMENTS OF OPERATIONSFOR THREE MONTHS ENDED NOVEMBER 30, 2006 AND 2005, AND FOR THEPERIOD FROM INCEPTION (MAY 5, 1998) TO NOVEMBER 30, 2006(Expressed in U.S. Dollars)(See Note 1 - Nature of Business and Basis of Presentation)(Unaudited)CumulativeMay 5, 1998Three MonthsThree Months(inception) toEndedEndedNovember 30, 2006November 30, 2006November 30, 2005ExpensesForeign exchange loss$2,875$107$193Management fees - related party203,074--Option fee2,000--Professional fees144,8847,05518,358Research and development (Note 4)184,98953,610-Investor relations380,970380,970-Travel and entertainment44,2795,2113,140Other operating expenses43,5202,8064,255Loss from operations1,006,591449,75925,946Other incomeInterest10,0422,340149Net loss for the period$(996,549)$(447,419)$(25,797)Loss per share:Basic and diluted$(0.010)$(0.001)Weighted average number ofcommon shares outstanding:Basic and diluted44,598,99641,124,600(The accompanying notes are an integral part of these consolidated financial statements)  4


OCTILLION CORP.(A Development Stage Company)CONSOLIDATED STATEMENT OF STOCKHOLDERS' EQUITY (DEFICIENCY)FROM MAY 5, 1998 (INCEPTION) TO NOVEMBER 30, 2006(Expressed in U.S. Dollars)(See Note 1 - Nature of Business and Basis of Presentation)(Unaudited)Deficit accumulatedPreferred StockCommon StockAdditionalSubscriptionduring theTotal stockholders'SharesAmountSharesAmountpaid-in capitalreceivabledevelopment stageequity (deficiency)Restricted common stockissued to related parties formanagement servicesat $0.003 per share-$-9,000,000$9,000$(6,000)$-$3,000Unrestricted common stock salesto third parties at $0.13 per share--1,125,0001,125148,875-150,000Net loss for the period-----(12,326)(12,326)Balance, August 31, 1998--10,125,00010,125142,875(12,326)140,674Net loss for the year-----(77,946)(77,946)Balance, August 31, 1999--10,125,00010,125142,875(90,272)62,728Net loss for the year-----(12,446)(12,446)Balance, August 31, 2000--10,125,00010,125142,875(102,718)50,282Net loss for the year-----(12,904)(12,904)Balance, August 31, 2001--10,125,00010,125142,875(115,622)37,378Net loss for the year-----(54,935)(54,935)Balance, August 31, 2002--10,125,00010,125142,875(170,557)(17,557)Restricted common stock issued toa related party to satisfy outstandingmanagement fees at $0.003 per shareon December 19, 2002--24,000,00024,00056,000-80,000


5


Restricted common stock issued to arelated party to satisfy outstandingmanagement fees at $0.003 per shareon March 18, 2003--6,999,6007,00016,332-23,332Net loss for the year-----(97,662)(97,662)Balance, August 31, 2004--41,124,60041,125215,207(288,006)(31,674)Net loss for the year-----(103,142)(103,142)Balance, August 31, 2005--41,124,60041,125215,207(391,148)(134,816)Issuance of common stock and warrantsat $0.17 per share on May 16, 2006--3,000,0003,000497,000-500,000Net loss for the year-----(157,982)(157,982)Balance, August 31, 2006--44,124,60044,125712,207-(549,130)207,202Exercise of Class A Warrants  at $0.167per share on November 10, and 14, 2006--3,000,0003,000497,000--$500,000Exercise of Class B Warrants  at $0.183per share on November 29, 2006--570,000570103,930--104,500Subscription receivable for 750,000 shares at$0.167 per share on exercise of Class A Warrants----(125,000)-(125,000)Subscription receivable for 570,000 shares at$0.183 per share on exercise of Class B Warrants----(104,500)-(104,500)Net loss for the period-$ --$ -$-$-$ (447,419)$ (447,419)Balance, November 30, 2006-$ -47,694,600$47,695$1,313,137$(229,500)$(996,549)$134,783(The accompanying notes are an integral part of these consolidated financial statements)


6


OCTILLION CORP.(A Development Stage Company)CONSOLIDATED STATEMENTS OF CASH FLOWSFROM THREE MONTHS ENDED NOVEMBER 30, 2006 AND 2005, AND FOR THEPERIOD FROM INCEPTION (MAY 5, 1998) TO NOVEMBER 30, 2006(Expressed in US Dollars)(See Note 1 - Nature of Business and Basis of Presentation)(Unaudited)CumulativeThree MonthsThree MonthsMay 5, 1998EndedEnded(inception) toNovember 30,November 30,November 30, 200620062005Cash flows used in operating activitiesNet loss for the period$(996,549)$(447,419)$(25,797)Adjustments to reconcile net loss tonet cash used in operating activities:- depreciation2,76920483- common stock issued for services3,000--- common stock issued for debt settlement103,332--Changes in non-cash working capital items:- decrease in prepaid expenses-1,496-- increase in accounts payable and accrued liabilities173,395160,52910,371- increase in accounts payable - related party30,000--Net cash used in operating activities(684,053)(285,190)(15,343)Cash flows from investing activitiesPurchase of equipment(3,645)--Net cash flows used in investing activities(3,645)--Cash flows from financing activitiesProceeds from the issuance of common stock1,025,000375,000-Repayment of promissory note(155,000)--Proceeds from promissory notes155,000--Net cash flows provided by financing activities1,025,000375,000-Increase in cash337,30289,810(15,343)Cash - beginning of period-247,49227,708Cash - end of period$337,302$337,302$12,365Supplemental cash flow information:Interest paid in cash$9,844$ -$-Income taxes paid in cash$ -$ -$-Supplemental noncash transaction:Accrued mangement fees converted to equity$103,332$ -$ -(The accompanying notes are an integral part of these consolidated financial statements)  7     OCTILLION CORP. (a development stage company)  Notes to Interim Unaudited Consolidated Financial Statements November 30, 2006 and 2005 (Expressed in U.S. Dollars)  1. Basis of Presentation and Going Concern Uncertainties  Octillion Corp. (the Company) was incorporated in the State of Nevada on May 5, 1998. The accompanying consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries, MicroChannel Technologies Corporation (MicroChannel) and Sungen Energy, Inc. (Sungen). MicroChannel was incorporated under the name MultiChannel Technologies Corporation on February 28, 2005 in the State of Nevada, and changed its name to MicroChannel on April 4, 2005. MicroChannel has no assets and no liabilities. Sungen was incorporated on July 11, 2006 in the State of Nevada and has no assets and no liabilities.  Octillion Corp., together with its wholly owned subsidiaries, is a technology incubator focused on the identification, acquisition, development and eventual commercialization of emerging technologies. Among the Companys current research and development activities are the development of 1) a patent-pending technology that could adapt existing home and office glass windows into ones capable of generating electricity from solar energy without losing significant transparency or requiring major changes in manufacturing infrastructure, and 2) technologies and products for peripheral and optic nerve damage and nerve regeneration.  The Company has not generated any revenues and has incurred losses of $996,549 since inception. The Company has incurred a loss of $447,419 during the three-month period ended November 30, 2006. In view of these conditions, the ability of the Company to continue as a going concern is in substantial doubt and dependent upon achieving a profitable level of operations and on the ability of the Company to obtain necessary financing to fund ongoing operations.  Management believes that its current and future plans enable it to continue as a going concern.  To meet these objectives, the Company completed a private placement for gross proceeds of $500,000 on May 16, 2006 and continues to seek other sources of financing in order to support existing operations and expand the range and scope of its business. However, there are no assurances that any such financing can be obtained on acceptable terms, if at all. Management believes that actions presently taken to revise the Company's operating and financial requirements provide the opportunity for the Company to continue as a going concern. The Company's ability to achieve these objectives cannot be determined at this time.  These consolidated financial statements do not give effect to any adjustments which would be necessary should the Company be unable to continue as a going concern and therefore be required to realize its assets and discharges its liabilities in other than the normal course of business and at amounts different from those reflected in the accompanying consolidated financial statements.  2. Presentation of Interim Information  The accompanying interim unaudited consolidated financial statements have been prepared in accordance with Form 10-QSB instructions and in the opinion of management contains all adjustments (consisting of only normal recurring adjustments) necessary to present fairly the financial position as of November 30, 2006, and the results of operations and cash flows for the three months ended November 30, 2006, and 2005. These results have been determined on the basis of generally accepted accounting principles and practices in the United States and applied consistently as those used in the preparation of the Company's 2006 Annual Report on Form 10-KSB.  Certain information and footnote disclosure normally included in the financial statements presented in accordance with generally accepted accounting principles in the United States have been condensed or omitted. It is suggested that the accompanying financial statements should be read in conjunction with the accompanying financial statements and notes thereto incorporated by reference in the Company's 2006 Annual Report on Form 10-KSB.   8   There have been no pronouncements issued that are not yet effective that would have a material effect on these financial statements.  3. Net Loss Per Common Share    Basic earnings or loss per share is based on the weighted average number of shares outstanding during the period of the financial statements.  Diluted earnings or loss per share are based on the weighted average number of common shares outstanding and dilutive common stock equivalents.  Effective September 1, 2006 the company enacted a 3 for 1 stock split.  All loss per share amounts in the financial statements are basic loss per share because the inclusion of stock options and warrants outstanding would be antidilutive. All per share and per share information are adjusted retroactively to reflect stock splits and changes in par value. The computation of basic and diluted loss per share is as follows:  Three months endedNovember 30,20062005Numerator - net loss available to commonstockholders$(447,419)$(25,797)Denominator - weighted average number ofcommon shares outstanding44,598,99641,124,600Basic and diluted loss per common share$ (0.010)$ (0.001)  4. Option interest  (a) Nerve Regeneration Technologies  On April 29, 2005, an Option Agreement (the Agreement) was executed between Iowa State Research Foundation Inc., (ISURF) and the Companys wholly-owned subsidiary, MicroChannel, pursuant to which the Company has acquired an option to obtain a license to certain nerve regeneration technologies being developed by ISURF. The Agreement has been amended to change the payment due dates on October 13, 2005. The consideration payable can be summarized as follows: ·payment of $2,000 (paid) in option fees upon execution of the Agreement;  · provide $155,839 to support the research project entitled “Conduits with Micropatterned Film for Peripheral Nerve Regeneration” with $50,000 (paid) due within 90 days of execution of the Agreement and four equal installments of $26,460 each due by January 31, 2006 (paid), April 30, 2006 (paid), July 31, 2006 (paid) and October 31, 2006 (paid in November 2006);  · contingent upon satisfactory progress and success of above project, provide additional $73,166 for the project entitled Conduits with Micropatterned Films for Optic Nerve Regeneration.  As of November 30, 2006, the Company has paid $155,839 to support the research project. As the research project has not reached the commercial development stage, the amounts incurred to support the project are thus expensed.  (b) Solar Energy Conversion Technology  In August 2006, the Company, through its wholly owned subsidiary, Sungen Energy Inc., entered into a Sponsored Research Agreement (Research Agreement) with scientists at the University of Illinois (UOI) for the development of a new patent-pending technology using nanosilicon photovoltaic solar cells that could convert normal home and office glass windows into ones capable of converting solar energy into electricity with limited loss of transparency and minimal changes in manufacturing infrastructure. The process of producing silicon nanoparticles is supported by 10 issued US patents, 7 pending US patents, 2 issued foreign counterpart patents and 19 pending foreign counterpart patents. The period of performance of the Research Agreement is for three years until August 22, 2008 and the Company has to pay $219,201 for the performance of the project, with $2,000 payable  9   upon execution of the agreement (paid), first installment of $27,150 payable on September 23, 2006 (paid) and the remaining 7 of $27,150 each payable every three months thereafter.  The Company has the option to enter into a commercial license for the project intellectual property by reimbursement of the related remaining out-of-pocket expenditures incurred by UOI and payment of royalties and fees to be negotiated, which should not to exceed 5% and $100,000 respectively.  As of November 30, 2006, the Company has paid $29,150 for the Research Agreement. As the research project has not reached the commercial development stage, the amounts incurred to support the project are thus expensed.  5. Equipment   November 30, 2006Computer equipment$2,486Office equipment1,1593,645Less: accumulated depreciation(2,769)$ 876  Depreciation expense charged to operations was $204 (2005: $83) for the three months ended November  30, 2006.  6. Capital Stock  At November 30, 2006 there were 1,000,000 shares of preferred stock (par value $0.01 per share) authorized, of which no shares were issued and outstanding.  The Board of Directors has the authority to issue such stock in one or more series, to fix the number of shares and to fix and determine the relative rights and preferences of the shares of any such series so established to the full extent permitted by the laws of the State of Nevada and the Articles of Incorporation.  7. Warrants  The movement of share purchase warrants can be summarized as follows:  Weighted averageNumber of warrantsexercise priceClass A WarrantsBalance, September 1, 20063,000,000$0.167Exercised(3,000,000)0.167Balance, November 30, 2006-Class B WarrantsBalance, September 1, 20063,000,000$0.183Exercised(570,000)0.183Balance, November 30, 20062,430,0000.183  As of November 30, 2006, 2,430,000 Class B warrants were outstanding which entitle the holders to purchase 2,430,000 common shares of the Company at $0.183 each expiring on May 17, 2009.   10   8. Related Party Transactions  Related party transactions are in the normal course of operations and are recorded at amounts established and agreed between the related parties.  During the three months periods ended November 30, 2006 and 2005, the current president and directors provided services to the Company for no compensation.  A management fee of $30,000 is accrued in accounts payable at November 30, 2006, and is due to the president of the Company for the services rendered in fiscal year 2003.  As of November 30, 2006, there were  39,999,600 shares held by two directors and a major shareholder of the Company that are considered "restricted shares" as that term is defined in Rule 144 as promulgated under the Securities Act. Restricted securities may be sold in the public market only if registered or if they qualify for an exemption from registration under Rules 144, 144(k) or 701 promulgated under the Securities Act.  Mr. Harmel S. Rayat is also a director and majority shareholder of each of International Energy, Inc., PhytoMedical Technologies, Inc., Entheos Technologies, Inc. and HepaLife Technologies, Inc.  9. Segment Information  The Companys business is considered as operating in one segment based upon the Companys organizational structure, the way in which the operations are managed and evaluated, the availability of separate financial results and materiality considerations.  10. Subsequent Event  In December 2006, warrants to purchase a total of 1,680,000 shares of common stock, having an aggregate exercise price of $308,000, were exercised.  11   Item 2. Management's Discussion and Analysis or Plan of Operations  Cautionary Statement Pursuant to Safe Harbor Provisions of the Private Securities Litigation Reform Act of 1995:  Except for the historical information presented in this document, the matters discussed in this Form 10-QSB for the three months ending November 30, 2006, and specifically in the items entitled "Management's Discussion and Analysis of Financial Condition and Results of Operations", or otherwise incorporated by reference into this document, contain "forward-looking statements" (as such term is defined in the Private Securities Litigation Reform Act of 1995). These statements are identified by the use of forward-looking terminology such as "believes", "plans", "intend", "scheduled", "potential", "continue", "estimates", "hopes", "goal", "objective", expects", "may", "will", "should" or "anticipates" or the negative thereof or other variations thereon or comparable terminology, or by discussions of strategy that involve risks and uncertainties. The safe harbor provisions of Section 21E of the Securities Exchange Act of 1934, as amended, and Section 27A of the Securities Act of 1933, as amended, apply to forward-looking statements made by the Company.  The reader is cautioned that no statements contained in this Form 10-QSB should be construed as a guarantee or assurance of future performance or results. These forward-looking statements involve risks and uncertainties, including those identified within this Form 10-QSB. The actual results that the Company achieves may differ materially from any forward-looking statements due to such risks and uncertainties. These forward-looking statements are based on current expectations, and the Company assumes no obligation to update this information. Readers are urged to carefully review and consider the various disclosures made by the Company in this Form 10-QSB and in the Company's other reports filed with the Securities and Exchange Commission that attempt to advise interested parties of the risks and factors that may affect the Company's business.  Overview  The Company was incorporated in the State of Nevada on May 5, 1998, under the name Octillion Corp., with an authorized capital stock of 100,000,000 shares of common stock, each with a par value of $.001, and 1,000,000 shares of preferred stock, each with a par value of $0.10. Octillion Corp., together with its wholly owned subsidiaries, MicroChannel Technologies Corporation (MicroChannel) and Sungen Energy, Inc. (Sungen), is a technology incubator focused on the identification, acquisition, development and eventual commercialization of emerging technologies.  Through established relationships with universities, research institutions, teaching hospitals and government agencies, the Company strives to identify technologies and business opportunities on the leading edge of innovation that have the potential of serving significant and unmet market needs.  Once a technology has been identified, the Company funds the research and development activities relating to the technology with the intention of ultimately, if warranted, licensing, commercializing and marketing the subject technology, either through internal resources, collaborative agreements or otherwise.  Unique to the Companys business model is the use of established research infrastructure owned by the various institutions the Company deals with, saving significant capital which would otherwise be required for such things as land and building acquisition, equipment and furniture purchases, and other incidental start up costs. As a result, the Company is able to benefit from leading edge research for significantly less than conventional organizations.  Among the Companys current research and development activities are the development of 1) a patent-pending technology that has the potential to adapt existing home and office glass windows into ones capable of generating electricity from solar energy without losing significant transparency or requiring major changes in manufacturing infrastructure, and 2) technologies and products for peripheral and optic nerve damage and nerve regeneration.  Plan of Operation  Octillion Corp., together with its wholly owned subsidiaries, is a technology incubator focused on the identification, acquisition, development and eventual commercialization of emerging technologies. To date we have not generated any revenues, have incurred losses since inception and have minimal assets.   12   In view of our financial condition, our ability for the Company to continue as a going concern is in substantial doubt and dependent our achieving a profitable level of operations and on our ability to obtain necessary financing to fund ongoing operations.  Management believes that our current and future plans enable us to continue as a going concern.  These financial statements do not give effect to any adjustments which would be necessary should we be unable to continue as a going concern and therefore be required to realize on our assets and discharge our liabilities other than in the normal course of business and at amounts different from those reflected in the accompanying financial statements.  Due to the start up nature of our business, we expect to incur losses as it expands.  To date, our cash flow requirements have been primarily met by debt and equity financings.  Management believes that we have sufficient cash flow to meet our capital requirements at least the next twelve months. Management expects to keep operating costs to a minimum until cash is available through financing or operating activities. If we are unable to generate profits or unable to obtain additional funds for our working capital needs, we have to cease operations.  Furthermore, there is no assurance the net proceeds from any successful financing arrangement will be sufficient to cover cash requirements during the initial stages of the Companys operations.  We plan to continue to seek other sources of financing on favourable terms; however, there are no assurances that any such financing can be obtained on favourable terms, if at all.  We expect to keep our operating costs to a minimum until cash is available through financing or operating activities.  There are no assurances that we will be successful in achieving these goals.  Liquidity and Capital Resources  As of November 30, 2006, the Company had a cash balance of $337,302. The Company has financed its operations primarily through cash on hand and warrant exercises during the three months ended November 30, 2006.  Net cash flows used in operating activities was $285,190, for the three month period ending November 30, 2006, compared to net cash flows used of $15,343 for the same period in 2005, primarily due to increases in investor relation costs and research and development costs.  The Company intends to seek additional funds from shareholders and third parties to finance the Companys operations.  Net cash provided by financing activities was $375,000 for the three months period ending November 30, 2006, compared to $0 for the same period in 2005. The Company has financed its operations primarily from cash on hand, and warrant exercises.  Related Party Transactions  Related party transactions are in the normal course of operations and are recorded at amounts established and agreed between the related parties.  During the three months periods ended November 30, 2006 and 2005, the current president and directors provided services to the Company for no compensation.  A management fee of $30,000 is accrued in accounts payable at November 30, 2006, and is due to the president of the Company for the services rendered in fiscal year 2003.  As of November 30, 2006, there were  39,999,600 shares held by two directors and a major shareholder of the Company that are considered "restricted shares" as that term is defined in Rule 144 as promulgated under the Securities Act. Restricted securities may be sold in the public market only if registered or if they qualify for an exemption from registration under Rules 144, 144(k) or 701 promulgated under the Securities Act.  Mr. Harmel S. Rayat is also a director and majority shareholder of each of International Energy, Inc., PhytoMedical Technologies, Inc., Entheos Technologies, Inc. and HepaLife Technologies, Inc.  Off-Balance Sheet Items  The Company currently has no off-balance sheet items.   13   Critical Accounting Policies  Our discussion and analysis or plan of operations is based upon our financial statements, which have been prepared in accordance with accounting principles generally accepted in the United States.  The preparation of these financial statements requires us to make estimates and judgments that affect the reported amounts of assets, liabilities, revenues and expenses, and related disclosure of contingent assets and liabilities.  On an on-going basis, we evaluate our estimates, including those related to income taxes and contingencies.  We base our estimates on historical experience and on various other assumptions that are believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources.  Actual results may differ from these estimates under different assumptions or conditions.  Management believes the following critical accounting policies reflect its more significant estimates and assumptions used in the preparation of its financial statements.  Income Taxes - We record a valuation allowance to reduce our deferred tax assets to the amount that is more likely than not to be realized. We have considered future market growth, forecasted earnings, future taxable income, and prudent and feasible tax planning strategies in determining the need for a valuation allowance. We currently have recorded a full valuation allowance against net deferred tax assets as we currently believe it is more likely than not that the deferred tax assets will not be realized.  Contingencies - We may be subject to certain asserted and unasserted claims encountered in the normal course of business. It is our belief that the resolution of these matters will not have a material adverse effect on our financial position or results of operations, however, we cannot provide assurance that damages that result in a material adverse effect on our financial position or results of operations will not be imposed in these matters.  We account for contingent liabilities when it is probable that future expenditures will be made and such expenditures can be reasonably estimated.  Risk Factors  We have sought to identify what we believe to be the most significant risks to our business.  However, we cannot predict whether, or to what extent, any of such risks may be realized nor can we guarantee that we have identified all possible risks that might arise. Investors should carefully consider all of such risk factors before making an investment decision with respect to our Common Stock. We provide the following cautionary discussion of risks, uncertainties and possible inaccurate assumptions relevant to our business. These are factors that we think could cause our actual results to differ materially from expected results. Other factors besides those listed here could adversely affect us.  We Have Experienced Significant Losses and Expect Losses To Continue For The Foreseeable Future.  We are a development stage company and have not generated any revenues since inception and we do not expect to generate any revenues for the foreseeable future.  We have incurred losses since inception.  We Currently Do Not Have, And May Never Develop, Any Commercialized Products.  We currently do not have any commercialized products or any significant source of revenue. We have invested substantially all of our time and resources over the last four years in the identification, research and development of innovative technologies.  Through our wholly owned subsidiary, MicroChannel Technologies Corporation, we have entered into an Option Agreement dated April 29, 2005, which was amended on October 13, 2005, with Iowa State Research Foundation, Inc. (ISURF).  ISURF owns by assignment the intellectual property entitled Patterned Substrates and Methods for Nerve Regeneration, (the ISURF nerve regeneration technology) which is covered by US Patent # 6,676,675 (the ISURF Patent). During the option period, in addition to funding the continuing development and enhancement of the ISURF nerve regeneration technology, we will evaluate the ISURF nerve regeneration technology to determine whether to acquire, pursuant to the terms of the Option Agreement, an exclusive worldwide license from ISURF to market the ISURF nerve regeneration technology in the field of nerve regeneration. The research will be conducted by Iowa State University of Science and Technology.   14   Through our wholly owned subsidiary, Sungen Energy, Inc., we entered into a Sponsored Research Agreement  (SRA) with the University of Illinois (UOI) on August 25, 2006. During the term of the SRA, which covers a period of August 23, 2006 to August 22, 2008, we will provide research and development funding and UOI will furnish the personnel, materials, services, facilities, and equipment for our joint research and development project entitled Power NanoWindows. Pursuant to the SRA, UOI has granted us an option to enter into good faith negotiation for a non-exclusive or exclusive commercial license to UOI project intellectual property (PIP), an exclusive commercial license to joint PIP, and a non-exclusive license to back ground intellectual property to the extent required to use specific UOI PIP or Joint PIP.  During the term of the SRA, we will determine whether to acquire a license to commercial the Power NanoWindows technology.  Even if we were to acquire any licenses, whether from ISURF or UOI, we will require additional research, development, clinical evaluation, regulatory approval, significant marketing efforts and substantial additional investment before our licenses can provide us with any revenue, if ever.  We cannot currently estimate with any accuracy the amount of these additional funds because it may vary significantly depending on results of current basic research and development and product testing, cost of acquiring exclusive licenses from ISURF and UOI, changes in the focus and direction of our research and development programs, competitive and technological advances, the cost of filing, prosecuting, defending and enforcing patent claims, the regulatory approval process, manufacturing, marketing and other costs associated with commercialization of products following receipt of regulatory approvals and other factors.  We May Require Additional Financing To Sustain Our Operations And Research Sponsorship Commitments.  Our independent registered public accounting firm has added an explanatory paragraph to their audit opinion issued in connection with the financial statements for the year ended August 31, 2006, relative to our ability to continue as a going concern. Our ability to obtain additional funding will determine our ability to continue as a going concern. Our financial statements do not include any adjustments that might result from the outcome of this uncertainty.  Our Option Agreement with ISURF requires us to provide $229,005 in total research funding and our SRA with UOI requires us to provide $218,201. Our ongoing research and development plans will require substantial capital. We do not have committed external sources of funding for our projects. We will require substantial funds to conduct additional basic research and development activities, preclinical studies, clinical trials and other activities relating to the successful commercialization of the ISURF nerve regeneration technology and the Power NanoWindows technology. We may not be able to obtain the additional funds we will require on acceptable terms, if at all. In addition, our cash requirements may vary materially from those now planned.  We cannot currently estimate with any accuracy the amount of these additional funds because it may vary significantly depending on results of current basic research and development and product testing, cost of acquiring an exclusive license from ISURF and UOI, changes in the focus and direction of our research and development programs, competitive and technological advances, the cost of filing, prosecuting, defending and enforcing patent claims, the regulatory approval process, manufacturing, marketing and other costs associated with commercialization of products following receipt of regulatory approvals and other factors.  If adequate funds are not available or prohibitively expensive when we require it, the consequences would be a material adverse effect on our business, operating results, financial condition and prospects.  We may be required to delay, reduce the scope of or terminate one or more or all of our research programs; to obtain funds through arrangements with collaborative partners or others that may require us to relinquish rights to certain the ISURF nerve regeneration technology or the Power NanoWindows technology,  or other technologies or products based upon the ISURF nerve regeneration technology or the Power NanoWindows technology that we would otherwise seek to develop or commercialize ourselves; or to license the rights to such technologies or products on terms that are less favorable to us than might otherwise be available. If we raise additional funds by issuing equity or debt securities, further dilution to stockholders may result and new investors could have rights superior to existing stockholders.  If We Ultimately Do Not Obtain The Necessary Regulatory Approvals For The Commercialization Of The ISURF Nerve Regeneration Technology or the Power NanoWindows Technology, We Will Not Achieve Profitable Operations And Your Investment May Be Lost.  Our ability to achieve profitability is dependent in part on ultimately obtaining regulatory approvals for the ISURF nerve regeneration technology and the Power NanoWindows technology and entering into agreements for  15   commercialization of such products.  At this time we have not submitted any products for regulatory approval nor do we have any agreements with any third parties regarding the commercialization of any products.  The failure to obtain any such necessary regulatory approvals or to enter into any such necessary agreements could delay or prevent us from achieving profitability.  This would result in the loss of your investment.  Moreover, even if the ISURF nerve regeneration technology or the Power NanoWindows technology, or any products based on the ISURF nerve regeneration technology or the Power NanoWindows technology are commercialized, we may still not achieve profitable operations, in which event we may need to curtail or cease our operations and as a result the value of your investment may be diminished or entirely eradicated.  The Success Of Our Research And Development Activities Is Uncertain. If The Research Efforts Are Not Successful, We Will Be Unable To Generate Revenues From Our Operations And We Will Have To Cease Doing Business.  We are at an early stage of development and we anticipate that we will remain engaged in research and development for a considerable period of time, at least through funding periods required under our agreement with Iowa State University and University of Illinois; if results warrant we may continue the research and development efforts towards the goal of commercializing the ISURF Nerve Regeneration Technology and the Power NanoWindows technology.  We may be unable to generate adequate revenue from operations or be able to financially support the level of research required to develop a commercially viable technology or product.  Research and development activities, by their nature, preclude definitive statements as to the time required and costs involved in reaching certain objectives. Actual costs may exceed the amounts we have budgeted and actual time may exceed our expectations. We cannot currently estimate with any accuracy the amount of these additional funds because it may vary significantly depending on results of current basic research and development and product testing, costs of acquiring an exclusive license from ISURF or UOI, changes in the focus and direction of our research and development programs, competitive and technological advances, the cost of filing, prosecuting, defending and enforcing patent claims, the regulatory approval process, manufacturing, marketing and other costs associated with commercialization of products following receipt of regulatory approvals and other factors. We anticipate that we will seek these funds from external sources, such as future offerings of equity or debt securities, including agreements with corporate partners and collaborators with respect to the development of our technology. In lieu, we may not be able to negotiate such arrangements or obtain the additional funds we will require on acceptable terms, if at all, in which event we may need to curtail or cease our operations and as a result the value of your investment may be diminished or entirely eradicated.  We May Not Receive an Exclusive License for the ISURF Nerve Regeneration Technology or the Power NanoWindows technology Or Obtain A License under Acceptable Terms and Conditions.  Our possible success is wholly dependent on obtaining, if warranted, an exclusive worldwide license from ISURF to market the ISURF nerve regeneration technology and a license from UOI to market the Power NanoWindows technology.  The receipt of these licenses is contingent on successful early stage research, and the submission of a development plan, as required in our Option Agreement with ISURF.  The development plan will require us to provide details such as timelines of major milestones for governmental approvals, marketing approach, competitive overview, and anticipated product launch date.  We may not be successful in presenting an acceptable development plan to, or in negotiating a license with, ISURF.  Among the items to be negotiated will be, but not limited to, licensing fees, reimbursement of patents costs, royalty rates, sub-licensing fees, and performance milestones upon reaching Phase I, II and III clinical trials and a milestone for obtaining the approval of the United States Food and Drug Administration (the FDA), which may require substantial cash payments from us.  We may not be able to make the required cash payments when due or achieve the necessary milestones and other requirements. If we do not, we will risk the loss of our license and our right to develop and market products, if any, derived from the ISURF nerve regeneration technology. Termination of our license, if obtained by us, could result in us being unable to continue development of the ISURF nerve regeneration technology or products derived from the ISURF nerve regeneration technology and production and marketing of approved products, if any, derived from the ISURF nerve regeneration technology. Consequently, termination of this license would have a material adverse effect on the business, financial condition and results of our operations.   16   We May Need Additional Licenses In The Future and If We Do Not Achieve Them We May Not Be Able To Market Products Developed From the ISURF Nerve Regeneration Technology or the Power NanoWindows Technology.  We may not retain all rights to developments, inventions, patents and other proprietary information resulting from any collaborative arrangements, whether in effect as of the date hereof or which may be entered into at some future time with third parties. As a result, we may be required to license such developments, inventions, patents or other proprietary information from such third parties, possibly at significant cost to us. Our failure to obtain any such licenses could have a material adverse effect on the business, financial condition and results of our operations. In particular, the failure to obtain a license could prevent us from using or commercializing our technology.  If We Lose The Services Of The Scientific Personnel Not Employed By Us, The Development Of The ISURF Nerve Regeneration Technology Will Be Substantially Delayed Or Precluded, Resulting In A Total Loss Of Our Investment In Technology.  We are dependent upon certain key collaborating scientific personnel who are not employed by us, including the principal investigator with respect to the ISURF nerve regeneration technology and the Power NanoWindows technology. The loss of these investigator's services could have a materially adverse effect on us, unless qualified replacements can be found. We have no control over whether our principal investigators or other scientific personnel will choose to remain involved with our projects. These individuals are not bound by contract to us nor employed by us. They might move on to other research.  The loss of their services may substantially delay if not preclude the continued development of the Nerve Regeneration Technology and the Power NanoWindows technology, in which event we may need to curtail or cease our operations and as a result the value of your investment may be diminished or entirely eradicated.  We May Not Be Able To Attract And Retain Qualified Personnel Either As Employees Or As Consultants And, Without Such Personnel We May Not Be Successful In Our Effort to Commercialize the ISURF Nerve Regeneration Technology Or The Power NanoWindows Technology.  Competition for qualified employees among companies in the biotechnology and solar cell industries  is intense. Our future success depends upon our ability to attract, retain and motivate highly skilled employees. Our present management has no clinical or other experience in the development of biotechnology or solar cell products. Attracting desirable employees will require us to offer competitive compensation packages, including stock options. In order to successfully commercialize our products, we must substantially expand our personnel, particularly in the areas of clinical trial management, regulatory affairs, business development and marketing.  We may not be successful in hiring or retaining qualified personnel. Managing the integration of new personnel and our growth generally could pose significant risks to our development and progress. The addition of such personnel may result in significant changes in our utilization of cash resources and our development schedule.  We Are Subject To Substantial Government Regulation, Compliance With Will Require Capital Expenditures Beyond Our Current Financial Means.  The production and marketing of products which may be developed from the ISURF nerve regeneration technology and our ongoing research and development activities are subject to extensive regulation and review by numerous governmental authorities. The ISURF nerve regeneration technology and any products derived from the technology must undergo rigorous preclinical and clinical testing and an extensive regulatory approval process before they can be marketed if they were to receive approval (which they may not in fact receive). This process makes it longer, harder and more costly to bring products which may be developed from our technologies to market.  The pre-marketing approval process can be particularly expensive, uncertain and lengthy, and a number of products for which the FDA approval has been sought by other companies have never been approved for marketing. In addition to testing and approval procedures, extensive regulations also govern marketing, manufacturing, distribution, labeling, and record-keeping procedures. If we do not comply with applicable regulatory requirements, such violations could result in warning letters, non-approval, suspensions of regulatory approvals, civil penalties and criminal fines, product seizures and recalls, operating restrictions, injunctions, and criminal prosecution.  Delays in or rejection of FDA, or other government entity, approval of the ISURF nerve regeneration technology (or products derived from the technology) may also adversely affect our business. Such delays or rejection may be encountered due to, among other reasons, government or regulatory delays, lack of efficacy during clinical trials,  17   unforeseen safety issues, slower than expected rate of patient recruitment for clinical trials, inability to follow patients after treatment in clinical trials, inconsistencies between early clinical trial results and results obtained in later clinical trials, varying interpretations of data generated by clinical trials, or changes in regulatory policy during the period of product development in the United States.  In the United States more stringent FDA oversight in product clearance and enforcement activities could result in our experiencing longer approval cycles, more uncertainty, greater risk, and higher expenses. Even if regulatory approval of a product is granted, this approval may entail limitations on uses for which the product may be labeled and promoted. It is possible, for example, that we may not receive FDA approval to market the ISURF nerve regeneration technology (or products derived from the technology) for broader or different applications or to market updated products that represent extensions of the ISURF nerve regeneration technology. In addition, assuming we obtain a license to the ISURF nerve regeneration technology, we may not receive FDA approval to export products, based on the ISURF nerve regeneration technology, in the future, and countries to which the products are to be exported may not approve them for import.   Any manufacturing facilities which we would utilize for the production of products based on the ISURF nerve regeneration technology would also be subject to continual review and inspection. The FDA has stated publicly that compliance with manufacturing regulations will be scrutinized more strictly. A governmental authority may challenge our compliance with applicable federal, state and foreign regulations. In addition, any discovery of previously unknown problems with the ISURF nerve regeneration technology, products derived from the technology, or manufacturing facilities used to manufacture the ISURF nerve regeneration technology (or any products derived from the technology) may result in restrictions on the products or the facility, including withdrawal of the product from the market or other enforcement actions.  From time to time, legislative or regulatory proposals are introduced that could alter the review and approval process relating to the ISURF nerve regeneration technology (or products derived from the technology). It is possible that the FDA will issue additional regulations further restricting the sale of the ISURF nerve regeneration technology (or products derived from the technology). Any change in legislation or regulations that govern the review and approval process relating to the ISURF nerve regeneration technology or to any related technologies that we subsequently develop, could make it more difficult and costly to obtain approval for new products based on the ISURF nerve regeneration technology, such additional technologies, or to produce, market, and distribute products derived from such technologies, if approved.  The Research To Be Conducted Regarding the ISURF Nerve Regeneration Technology Is Based On The Use Of Human Stem Cells Obtained From Fetal Tissue, The Use Of Which May Be Limited Or Prohibited Under Federal And State Laws.  The restrictions relating to the use of human stem cells obtained from fetal tissue change from time to time and may become more onerous. Additionally, we may not be able to identify or develop reliable sources for the cells necessary for our potential products-that is, sources that follow all state and federal guidelines for cell procurement. Further, we may not be able to obtain such cells in the quantity or quality sufficient to satisfy the commercial requirements for the ISURF nerve regeneration technology. As a result, we may be unable to develop the ISURF nerve regeneration technology or produce our products based on the ISURF nerve regeneration technology in a profitable manner.  Although we do not use embryonic stem cells, government regulation and threatened regulation of embryonic tissue may lead top researchers to leave the field of stem cell research, or the country, in order to assure that their careers will not be impeded by restrictions on their work. Similarly, these factors may induce the best graduate students to choose other fields less vulnerable to changes in regulatory oversight, thus exacerbating the risk, discussed below, that we may not be able to attract and retain the scientific personnel we need in face of the competition among pharmaceutical, biotechnology and health care companies, universities and research institutions for what may become a shrinking class of qualified individuals. In addition, constraints on the use of embryonic stem cells could be extended to use of fetal stem cells. Moreover, it is possible that concerns regarding research using embryonic stem cells will impact our ability to attract collaborators and investors; this, in turn, could adversely affect our stock price.   18   Compliance With Environmental Regulations, Or Dealing With Potentially Harmful Biological Materials Or Hazardous Materials Involved In Our Research And Development, May Require Us To Divert Our Limited Capital Resources.  Our research and development programs do not generally involve the handling of potentially harmful biological materials or hazardous materials, but they may occasionally do so. Iowa State University and we are subject to federal, state and local laws and regulations governing the use, handling, storage and disposal of hazardous and biological materials. If violations of environmental, health and safety laws occur, we could be held liable for damages, penalties and costs of remedial actions. These expenses or this liability could have a significant negative impact on our business, financial condition and results of operations. We may violate environmental, health and safety laws in the future as a result of human error, equipment failure or other causes. Environmental laws could become more stringent over time, imposing greater compliance costs and increasing risks and penalties associated with violations. We may be subject to potentially conflicting and changing regulatory agendas of political, business and environmental groups. Changes to or restrictions on permitting requirements or processes, hazardous or biological material storage or handling might require an unplanned capital investment or relocation. Failure to comply with new or existing laws or regulations could harm our business, financial condition and results of operations.  Our Research And Development Program May Be Adversely Affected by The Significant Risks Associated With The Use Of Human Test Subjects.  Assuming that we are able to further develop and enhance the ISURF nerve regeneration technology to a point where human clinical trials are required, such trials will be dependent upon, among other factors, the rate of patient enrollment. Patient enrollment is a function of many factors, including the size of the patient population, the nature of the protocol, the availability of alternative treatments, the proximity of eligible patients to clinical sites and the eligibility criteria for the study. Delays in planned patient enrollment might result in increased costs and delays, which could have a material adverse effect on us. We, our future collaborators, if any, or the FDA or other regulatory agencies may suspend clinical trials at any time if the subjects or patients participating in such trials are being exposed to unacceptable health risks. In addition, clinical trials are often conducted with patients having the most advanced stages of disease. During the course of treatment, these patients can suffer adverse medical effects or die for reasons that may not relate to the product being tested, but which can nevertheless affect adversely any results generated from clinical trials.  We May Be Required To Comply With Rules Regarding Animal Testing and This May Limit the Success Of Our Research And Development Program.  The research and development efforts regarding the ISURF nerve regeneration technology, which are sponsored by us, involve laboratory animals. We may be adversely affected by changes in laws, regulations or accepted procedures applicable to animal testing or by social pressures that would restrict the use of animals in testing or by actions against us or our collaborators by groups or individuals opposed to such testing.  Our Research And Development Program Is In The Preliminary Development Stage And The Results We Attain May Not Prove To Be Adequate For Purposes of Developing and Commercializing Any Products Or Otherwise To Support A Profitable Business Venture.  Our research and development program is the preliminary development stage.  It may not be successful.  Our research program is targeting nerve regeneration technologies.We will require significant further research, development, testing, regulatory approvals and significant additional investment before we will be in a position to attempt to commercialize products derived from our research and development program. The ultimate results of our ongoing research program may demonstrate that the technologies being researched by us may be ineffective, unsafe or unlikely to receive necessary regulatory approvals. If such results are obtained, we will be unable to create marketable products or generate revenues and we may have to cease operations.  We have not submitted any products or any technologies that are the subject of, or result from, our research and development activities for regulatory approval or clearances. Even if our research is successful, the process of obtaining necessary FDA approvals or clearances can take years and is expensive and full of uncertainties. Additionally, approved products are subject to continuing FDA requirements relating to quality control and quality assurance, maintenance of records, reporting of adverse events and product recalls, documentation, labeling and  19   promotion of medical products.  Compliance with such regulations may prove to be costly and may limit our ability to attain profitable operations.  We Lack Sales and Marketing Experience and Will Likely Rely On Third Party Marketers.  If we obtain FDA (and other approvals) of the ISURF nerve regeneration technology (or any products derived from the technology), we expect to market and sell or otherwise commercialize the ISURF nerve regeneration technology (or any products derived from the technology) through distribution, co-marketing, co-promotion or licensing arrangements with third parties. We have no experience in sales, marketing or distribution of medical products and our current management and staff is not trained in these areas. To the extent that we enter into distribution, co-marketing, co-promotion or licensing arrangements for the marketing or sale of the ISURF nerve regeneration technology (or any products derived from the technology) any revenues received by us will be dependent on the efforts of third parties. If any of such parties were to breach or terminate its agreement with us or otherwise fail to conduct marketing activities successfully and in a timely manner, the commercialization of the ISURF nerve regeneration technology (or any products derived from the technology) would be delayed or terminated.  Once The ISURF Nerve Regeneration Technology (Or Any Products Derived From The Technology) Are Marketed And Sold We May Be Exposed To Product Liability Claims, Which, In The Absence Of Adequate Insurance, Will Adversely Affect Our Financial Condition, And, Possibly, Our Ability To Continue To Market Any Of Our Products.  If we obtain a license to the ISURF nerve regeneration technology and ultimately develop products based on the technology, we will be involved either directly or indirectly in the manufacturing and distribution of the ISURF nerve regeneration technology and products derived from the technology.  We will then be exposed to the financial risk of liability claims in the event that the use of the ISURF nerve regeneration technology and products derived from the technology results in personal injury or death. As a result, we experience losses due to product liability claims in the future, for which we may not have adequate, if any, insurance.  A product liability claim, product recall or other claim, or claims for uninsured liabilities or in excess of insured liabilities, may have a material adverse effect on our business, financial condition and results of operations. We do not currently carry any general or product liability insurance. If a claim against us results in a court awarding a large monetary judgment which we cannot pay, we may have to cease operations.  We Expect To Operate In A Highly Competitive Market; In Attempting To Commercialize the ISURF Nerve Regeneration Technology Or The Power NanoWindows Technology, We Will Face Various Forms Of Competition From Other Companies, Products And Technologies.  Our commercial success will depend on our ability and the ability of our sublicensees, if any, to compete effectively in product development areas such as, but not limited to, safety, efficacy, ease of use, patient or customer compliance, price, advertising and marketing and distribution. Our competitors may succeed in developing products that are more effective than any products derived from our research and development efforts or that would render such products obsolete and non-competitive. The biomedical technology and solar cell industries are characterized by intense competition, rapid product development and technological change. Most of the competition that we encounter will come from companies, research institutions and universities who are researching and developing technologies and products similar to or competitive with any we may develop.  These companies enjoy numerous competitive advantages, including:  -  significantly greater name recognition; -  established relations with healthcare professionals, customers and third-party payors; -  established distribution networks; -  additional lines of products, and the ability to offer rebates, higher discounts or incentives to gain a competitive advantage; -  greater experience in conducting research and development, manufacturing, clinical trials, obtaining regulatory approval for products, and marketing approved products; and -  greater financial and human resources for product development, sales and marketing, and patent litigation.  As a result, we may not be able to compete effectively against these companies or their products.   20   Concentration Of Ownership Among Our Directors, Executive Officers, And Principal Stockholders May Prevent New Investors From Influencing Significant Corporate Decisions.  As of January 11, 2007, our directors, executive officers, holders of more than 5% of our common stock, and their affiliates, beneficially own approximately 81% of our outstanding common stock. As a result, these stockholders, subject to any fiduciary duties owed to our other stockholders under Nevada law, will be able to exercise a controlling influence over matters requiring stockholder approval, including the election of directors and approval of significant corporate transactions, and will have significant control over our management and policies. Some of these persons or entities may have interests that are different from yours. For example, these stockholders may support proposals and actions with which you may disagree or which are not in your interests. The concentration of ownership could delay or prevent a change in control of our company or otherwise discourage a potential acquirer from attempting to obtain control of our company, which in turn could reduce the price of our common stock. In addition, these stockholders, some of whom have representatives sitting on our board of directors, could use their voting influence to maintain our existing management and directors in office, delay or prevent changes of control of our company, or support or reject other management and board proposals that are subject to stockholder approval, such as amendments to our employee stock plans and approvals of significant financing transactions.  We May Compete For the Time and Efforts Of Our Officers And Directors.  Our officers and directors are also officers and directors of other companies, and we may have to compete with the other companies for their time, attention and efforts.  Except for Ms. DuMoulin, who anticipates devoting her full  time and attention to our matters, none of our officers and directors anticipate devoting more than approximately five (5%) percent of their time to our matters.   We currently have no employment agreements with any of our officers and directors imposing any specific condition on our officers and directors regarding their continued employment by us.  Because Our Stock Is A Penny Stock, You May Find It Difficult To Sell The Shares Of Our Common Stock You Acquired.  Our common stock is a penny stock as that term is defined in SEC rules and regulations. Generally, a "penny stock" is a common stock that is not listed on a securities exchange and trades for less than $5.00 a share. Prices often are not available to buyers and sellers and the market may be very limited. Penny stocks in start-up companies are among the riskiest equity investments. Broker-dealers who sell penny stocks must provide purchasers of these stocks with a standardized risk-disclosure document prepared by the Securities and Exchange Commission. The document provides information about penny stocks and the nature and level of risks involved in investing in the penny stock market. A broker must also give a purchaser, orally or in writing, bid and offer quotations and information regarding broker and salesperson compensation, make a written determination that the penny stock is a suitable investment for the purchaser, and obtain the purchaser's written agreement to the purchase. Many brokers choose not to participate in penny stock transactions. Because of the penny stock rules, there is less trading activity in penny stock and you are likely to have difficulty selling your shares of our stock.  We Do Not Intend To Pay Dividends For The Foreseeable Future.  We currently intend to retain future earnings, if any, to support the development and expansion of our business and do not anticipate paying cash dividends in the foreseeable future. Our payment of any future dividends will be at the discretion of our board of directors after taking into account various factors, including but not limited to our financial condition, operating results, cash needs, growth plans and the terms of any credit agreements that we may be a party to at the time. Accordingly, investors must rely on sales of their common stock after price appreciation, which may never occur, as the only way to realize their investment. Investors seeking cash dividends should not purchase the units offered by us pursuant to this prospectus.  Enforceability Of Civil Liabilities Against Foreign Persons  We are a company  incorporated  under the laws of Nevada but because we are a  company  headquartered  in  Canada  our  investors  may  have  difficulty enforcing civil liabilities  under the U.S. federal  securities laws against our officers and  directors,  especially  because some of our directors and officers reside in Canada.  Because some of our assets are located  outside the U.S.,  it may be  difficult  for an  investor  to sue,  for any  reason,  us or any of our directors  or officers  through U.S. jurisdictions.  If an investor was able to obtain a judgment against us or any of our directors or officers in a U.S. court based on U.S. securities laws or other reasons, it may be difficult to  21   enforce such judgment in Canada. We are uncertain as to the enforceability, in original actions in Canadian courts, of liability based upon the U.S. federal securities laws and as to the enforceability in Canadian courts of judgments of U.S. courts obtained in actions based upon the civil liability provisions of the U.S. federal securities laws.  ITEM 3.   Controls and Procedures  Our management is responsible for establishing and maintaining adequate internal control over financial reporting, as such term is defined in Rules 13a-15(f) and 15d-15(f) under the Securities Exchange Act of 1934, as amended. A companys internal control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles. A companys internal control over financial reporting includes those policies and procedures that (i) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and disposition of the assets of the company; (ii) provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the company are being made only in accordance with authorizations of management and directors of the company; and (iii) provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use, or disposition of the companys assets that could have a material effect on the financial statements.  An evaluation was performed under the supervision of our management, including our Chief Executive Officer and Chief Financial Officer, of the effectiveness of the design and operation of the Companys disclosure controls and procedures (as defined in Securities Exchange Act of 1934 (the Exchange Act) Rules 13a-15(e) and 15d-15(e)) as of the end of the period covered by this report. Based on that evaluation, our management, including our Chief Executive Officer and Chief Financial Officer, concluded that our disclosure controls and procedures were effective to provide reasonable assurance that information we are required to disclose in reports that we file or submit under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in SEC rules and forms.  Notwithstanding the foregoing, there can be no assurance that our disclosure controls and procedures will detect or uncover all failures of persons associated with us to disclose material information otherwise required to be set forth in our periodic reports. There are inherent limitations to the effectiveness of any system of disclosure controls and procedures, including the possibility of human error and the circumvention or overriding of the controls and procedures. Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate. Accordingly, even effective disclosure controls and procedures can only provide reasonable, not absolute, assurance of achieving their control objectives.  There have been no significant changes in internal controls, or in factors that could significantly affect internal controls, subsequent to the date that management, including the Chief Executive Officer and the Chief Financial Officer, completed their evaluation  22   PART II  Other Information  Item 1.   Legal Proceedings  None  Item 2.   Unregistered Sales of Equity Securities and Use of Proceeds  None  Item 3.   Defaults Upon Senior Securities  None  Item 4.   Submission of Matters to a Vote of Security Holders  None  Item 5.   Other Information  None  Item 6.   Exhibits and Reports on Form 8-K  (a) Exhibits  31.1 Certification of the Chief Executive Officer pursuant to Rule 13a-14(a)  31.2 Certification of the Chief Financial Officer pursuant to Rule 13a-14(a)  32.1 Certification by the Chief Executive Officer pursuant to 18 U.S.C. 1350 as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002  32.2 Certification by the Chief Financial Officer pursuant to 18 U.S.C. 1350 as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002  (b) Reports on Form 8-K  September 14, 2006: On September 8, 2006, the Company announced the appointment of Mr. Harmel S. Rayat to its Board of Directors. On September 11, 2006, Octillion Corp. issued a news release to announce that it has entered into a Sponsored Research Agreement with scientists at the University of Illinois in Urbana-Champaign for the development of a new patent-pending technology using nanosilicon photovoltaic solar cells that could convert normal home and office glass windows into ones capable of converting solar energy into electricity.  October 10, 2006: On October 9, 2006, the Company announced the appointment of Dr. Kaiyo Nedd to its Board of Directors.   23   SIGNATURES  Pursuant to the requirements of Sections 13 or 15 (d) of the Securities and Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned,  thereunto duly  authorized on this 11th day of January, 2007.   Octillion Corp.    /s/ Terri DuMoulin  Terri DuMoulin  President, Chief Executive Officer    Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons  on  behalf of the registrant and in capacities and on the dates indicated.    Signature Title Date   /s/ Terri DuMoulin President, Chief Executive Officer January 11, 2007 Terri DuMoulin Principal Financial Officer, Director    24